CClinicalTrials.gg
CompletedNCT01768754Updated Mar 12, 2013

Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease

An observational study in Chronic Obstructive Pulmonary Disease, sponsored by West Park Healthcare Centre. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-12.

Sponsored by West Park Healthcare Centre · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
29
Ages
18 Years and older
Sex
All
01

Study summary

A growing body of evidence suggests that in individuals with chronic lung disease their walk speed is related to their daily function and quality of life. It is possible to assess their usual (routine) and fast walking speeds by getting them to walk in a flat hallway.

In individuals with chronic lung disease, we anticipate that their usual walk speed will be helpful in exercise prescription and use in multidimensional scoring systems. However, it is important to first determine the measurement properties of these two walk speeds.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Exercise testing
  • Functional status
  • Pulmonary rehabilitation
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 29 is below the median of 157 across 929 observational studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

West Park Healthcare Centre is the lead sponsor of 27 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stable moderate-severe COPD will be recruited from those under the care of a respirologist at West Park Health Care Centre

Inclusion criteria

  • Clinical and spirometric diagnosis of COPD
  • Able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Unstable cardiovascular disease
  • Acute respiratory exacerbation within 4 weeks
  • Neurologic or orthopedic limitation to walking
  • Inability to comprehend instructions in English
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
29 participants (actual)
Patient registry
No

Groups and cohorts

  • COPD patients

    Usual and Fast Walking Speeds

    Behavioral: Usual and Fast Walking Speeds

Interventions

  • BehavioralUsual and Fast Walking Speeds

    Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.

06

What researchers measure

Primary outcomes

  1. Coefficient of repeatability for usual and fast walk speeds

    Participants will be asked to demonstrate their usual and fast walk speeds over the middle 10 meters of a 30 meter straight track using optical sensors and a hand-held stopwatch. Participants will be instructed to walk at their 'usual' and 'fast' speeds as standardized instructions. The walk test will be repeated after a 5 minute rest and then repeated on two subsequent days, at the same time of day, within one week. This will be simply observational in nature with no planned intervention aside for controlling walking environment. The primary outcome is going to report a change in walk speeds from baseline and at 1 and 2 days using repeated measures as described by Bland and Altman (reference below).

    Time frame: At baseline and over 1 week period.

Secondary outcomes

  1. Agreement in walk speeds between optical sensors and stopwatch

    Assess agreement between the use of optical sensors and stop watch time for the usual and fast walk speeds.

    Time frame: Baseline and over 1 week of testing.

  2. Agreement in the Bode Index using six minute walk distance and usual walk speed.

    To assess agreement in the calculated Bode Index using the six minute walk distance versus estimated usual walk speed distance over 6 minutes.

    Time frame: Baseline

Other outcomes

  1. Precision of achieving a targeted endurance time using the usual and fast walking speeds.

    The usual and fast walk speeds will be used to predict the test speed for a high-intensity constant-speed endurance test that will achieve an acceptable endurance time of 2-15 minutes.

    Time frame: Baseline

07

Study locations

1 site
  • Westpark Health Care Centre
    Toronto, Ontario M6M 2J5, Canada
08

References and documents

Publications

  • Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999 Jun;8(2):135-60. doi: 10.1177/096228029900800204. PubMed 10501650 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01768754
Lead sponsor
West Park Healthcare Centre
Responsible party
Roger Goldstein (Director, Respiratory Medicine, West Park Healthcare Centre) — Principal investigator
First posted
Jan 15, 2013
Start date
Jul 2012
Primary completion
Feb 2013
Completion
Mar 2013
Last update
Mar 12, 2013

Study contacts

Roger Goldstein, MD, FRCPC
principal investigator · Westpark Healthcare Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion